Identification of Determinants Required for Agonistic and Inverse Agonistic Ligand Properties at the ADP Receptor P2Y12

@article{Schmidt2013IdentificationOD,
  title={Identification of Determinants Required for Agonistic and Inverse Agonistic Ligand Properties at the ADP Receptor P2Y12},
  author={Philipp Schmidt and Lars Ritscher and Elizabeth N. Dong and Thomas Hermsdorf and Maxi C{\"o}ster and Doreen Wittkopf and Jens Meiler and Torsten Sch{\"o}neberg},
  journal={Molecular Pharmacology},
  year={2013},
  volume={83},
  pages={256 - 266}
}
The ADP receptor P2Y12 belongs to the superfamily of G protein–coupled receptors (GPCRs), and its activation triggers platelet aggregation. Therefore, potent antagonists, such as clopidogrel, are of high clinical relevance in prophylaxis and treatment of thromboembolic events. P2Y12 displays an elevated basal activity in vitro, and as such, inverse agonists may be therapeutically beneficial compared with antagonists. Only a few inverse agonists of P2Y12 have been described. To expand this… 

Tables from this paper

John Daly Lecture: Structure-guided Drug Design for Adenosine and P2Y Receptors☆
Agonist-bound structure of the human P2Y12 receptor
TLDR
The agonist-bound P2Y12R structure answers long-standing questions surrounding P2y12R–agonist recognition, and reveals interactions with several residues that had not been reported to be involved in agonist binding.
Membrane Environment Modulates Ligand-Binding Propensity of P2Y12 Receptor
TLDR
All-atom molecular dynamics simulations of the full-length P2Y12 receptor in three different membrane environments and in two possible conformations derived from available crystal structures show that accounting for internal protein dynamics, strongly modulated by its lipid environment, is crucial for correct assessment of the ligand binding to P2y12.
Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information
TLDR
A structure-based approach consistently rationalized the main structure–activity relationships within each ligand class, giving useful information for designing improved ligands.
Structure, Pharmacology and Roles in Physiology of the P2Y12 Receptor.
TLDR
There is evidence for changes in P2Y12 receptor expression in CNS pathologies including Alzheimer’s diseases and multiple sclerosis, and the recently published three-dimensional crystal structures of the human P2y12 receptor in complex with agonists and antagonists will facilitate the development of novel therapeutic agents with reduced adverse effects.
Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor.
TLDR
2 novel modes of action of ticagrelor are described, inhibition of platelet ENT1 and inverse agonism at the P2Y12R that contribute to its effective inhibition of Platelet activation.
Pharmacology of P2Y receptors
...
...

References

SHOWING 1-10 OF 67 REFERENCES
Identification of a Potent Inverse Agonist at a Constitutively Active Mutant of Human P2Y12 Receptor
TLDR
This is the first report of a cell line stably expressing a constitutively active mutant of human platelet P2Y12 receptor and the identification of potent inverse agonist.
Generation of an agonistic binding site for blockers of the M(3) muscarinic acetylcholine receptor.
TLDR
It is found that atropine still blocks carbachol-induced activation of the M(3)R mutants in the yeast expression system by binding at the high-affinity-binding site (Ki approximately 10 nM).
Comparison of three GPCR structural templates for modeling of the P2Y12 nucleotide receptor
TLDR
Ligand docking to the CXCR4-based model of the P2Y12R predicted poses of both reversibly and irreversibly-binding small molecules, consistent with observed pharmacology and mutagenesis studies.
Identification and analysis of functionally important amino acids in human purinergic 12 receptor using a Saccharomyces cerevisiae expression system
TLDR
The results of this study demonstrate that positions 181, 256, 265 and 280 of P2Y12 are important for the functional integrity of the receptor, and K280 appears to be a crucial feature of the P2y12 ligand‐binding pocket.
The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts.
  • P. Savi, J. Zachayus, J. Herbert
  • Biology, Chemistry
    Proceedings of the National Academy of Sciences of the United States of America
  • 2006
TLDR
The mechanism of action of clopidogrel and of its active metabolite (Act-Met) on P2Y12 receptors is deciphered and the existence of homooligomeric complexes of P2y12 receptors at the surface of mammalian cells and in freshly isolated platelets is demonstrated.
Delineation of ligand binding and receptor signaling activities of purified P2Y receptors reconstituted with heterotrimeric G proteins
TLDR
The laboratory has purified several P2Y receptors with the goal of providing molecular insight into their ligand binding properties, G protein signaling selectivities, and regulation by RGS proteins and other signaling cohorts, and utilized this reconstitution system to assess the action of various nucleotide agonists and antagonists.
The ligand specificity of the G-protein-coupled receptor GPR34.
TLDR
The results of the present study suggest that lyso-PS has only a random agonistic activity at some GPR34 orthologues and the search for the endogenous agonist should consider additional chemical entities.
Purification and functional reconstitution of the human P2Y12 receptor.
TLDR
The results illustrate that the signaling properties of the P2Y12-R can be studied as a purified protein under conditions that circumvent the complications that occur in vivo because of nucleotide metabolism and interconversion as well as nucleotide release.
Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270.
TLDR
The results indicate that the human P2Y(12) receptor has 2 free cysteines in its extracellular domains (Cys17 and Cys270), both of which are targets of thiol reagents, and is inactivate by the thiol agent p-chloromercuribenzene sulfonic acid and active metabolites from antiplatelet drugs.
...
...